CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma...
Phase 2
Berlin, Germany and 24 other locations
therapy per local standard of care \[SoC\], best supportive care \[BSC\] on protocol survivor follow up) in patients with advanced non-ocular melanoma...
Phase 3
Berlin, Germany and 65 other locations
(PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma...
Phase 3
Berlin, Germany and 110 other locations
binimetinib, and pembrolizumab) given together for the treatment of melanoma that:* is advanced or metastatic (spread to other parts of the ...
Phase 3
Berlin, Germany and 227 other locations
At least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observat...
Phase 3
Berlin, Germany and 3 other locations
To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investig...
Phase 2
Berlin, Germany and 55 other locations
antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotin...
Phase 2, Phase 3
Berlin, Germany and 65 other locations
of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma ...
Phase 2
Berlin, Germany and 65 other locations
with previously untreated unresectable or metastatic (advanced) melanoma.Patients will be stratified on the basis of the following factors; ...
Phase 3
Berlin, Germany and 111 other locations
not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma...
Phase 3
Berlin, Germany and 189 other locations
Clinical trials
Research sites
Resources
Legal